抗体药物复合体契约製造市场规模、份额、成长分析（按开发阶段、製程组件、目标指示、抗体生成、抗体来源和地区）- 产业预测 2025-2032

预计 2023 年全球抗体药物复合体契约製造市场价值将达到 86 亿美元，并将从 2024 年的 96.4 亿美元增长到 2032 年的 240.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 12.1%。

根据市场洞察，全球抗体药物复合体(ADC)契约製造製造业正在经历显着增长，这得益于对标靶癌症治疗的日益增长的偏好以及对生技药品研发的大量投资。全球癌症发生率的上升推动了对精准医疗的需求，使 ADC 成为值得关注的治疗选择。此外，ADC 的製造复杂性需要生物偶联专业知识、先进的控制和分析测试，从而创造了新的商机。在 FDA 和 EMA 等监管机构的快速核准支持下，这将进一步刺激需求。相反，高製造成本、严格的法律规范、缺乏专业的契约製造组织 (CMO) 以及供应链问题等挑战可能会在不久的将来阻碍市场成长和渗透。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 原料分析

抗体药物复合体契约製造市场规模（按发展阶段和复合年增长率）（2025-2032）

• 市场概况
• 第一阶段
• 第二阶段
• 第三阶段

抗体药物复合体契约製造市场规模（按製程组件和复合年增长率）（2025-2032）

• 市场概况
• 抗体
• HPAPI/细胞毒性有效载荷
• 键/连接子
• 填充/整理

抗体药物复合体契约製造市场规模（按目标适应症和复合年增长率）（2025-2032）

• 市场概况
• 固态肿瘤
• 血液系统肿瘤
• 其他的

抗体药物复合体契约製造市场规模（以抗体生成和复合年增长率）（2025-2032）

• 市场概况
• 第二代
• 第三代
• 第四代
• 新一代

抗体药物复合体契约製造市场规模（按抗体来源和复合年增长率）（2025-2032）

• 市场概况
• 人性化
• 嵌合体
• 老鼠
• 其他的

抗体药物复合体契约製造市场规模（按连接体类型和复合年增长率）（2025-2032）

• 市场概况
• 马来酰亚胺
• SMCC
• 四肽基连接体
• 缬氨酸-瓜氨酸
• 其他的

抗体药物复合体契约製造市场规模（按最终用户和复合年增长率划分）（2025-2032）

• 市场概况
• 製药公司
• 生技公司-30%
• 学术研究机构
• 其他的

抗体药物复合体契约製造市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司份额按部门分析
  • 收益同比比较（2022-2024 年）

主要企业简介

• Lonza Group AG（Switzerland）
• WuXi XDC（China）
• Catalent, Inc.（USA）
• Piramal Pharma Solutions（India）
• MilliporeSigma（Germany）
• Sterling Pharma Solutions（UK）
• AGC Biologics（USA）
• Cerbios-Pharma SA（Switzerland）
• CARBOGEN AMCIS（Switzerland）
• Curia（USA）
• Abzena PLC（UK）
• WuXi Biologics（Cayman Islands）
• Ajinomoto Bio-Pharma Services（Japan）
• Axplora（France）
• Sartorius AG（Germany）
• Samsung Biologics（South Korea）
• Recipharm AB（Sweden）
• AbbVie Contract Manufacturing（USA）
• Formosa Laboratories（Taiwan）
• Veranova（USA）

结论和建议

Global Antibody Drug Conjugates Contract Manufacturing Market size was valued at USD 8.6 billion in 2023 and is poised to grow from USD 9.64 billion in 2024 to USD 24.04 billion by 2032, growing at a CAGR of 12.1% during the forecast period (2025-2032).

Market insights indicate a significant uptick in the global antibody drug conjugates (ADCs) contract manufacturing sector, driven by the rising preference for targeted cancer therapies and substantial investments in biologics R&D. The increasing prevalence of cancer globally has fueled the demand for precision medicine, positioning ADCs as a notable treatment option. Moreover, the complexity involved in ADC manufacturing-requiring specialized bioconjugation expertise, advanced containment, and analytical testing-presents new business opportunities. Support from regulatory bodies, including the FDA and EMA, through expedited approvals enhances demand further. Conversely, challenges such as high manufacturing costs, stringent regulatory frameworks, a scarcity of specialized contract manufacturing organizations (CMOs), and supply chain issues may impede market growth and penetration in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates Contract Manufacturing Market Segments Analysis

Global Antibody Drug Conjugates Contract Manufacturing Market is segmented by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User and region. Based on Stage of Development, the market is segmented into Phase I, Phase II and Phase III. Based on Process Component, the market is segmented into Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish. Based on Target Indication, the market is segmented into Solid Tumors, Hematological Tumors and Others. Based on Antibody Generation, the market is segmented into Second Generation, Third Generation, Fourth Generation and Next Generation. Based on Antibody Origin, the market is segmented into Humanized, Chimeric, Murine and Others. Based on Type of Linker, the market is segmented into Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies - 30%, Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Drug Conjugates Contract Manufacturing Market

The expanding therapeutic applications of various antibody drug conjugates have prompted pharmaceutical and biotech companies to enhance their investments in research and development. As clinical trials advance, there is a heightened demand for manufacturing partners that can provide scalable and compliant production solutions. Furthermore, the rising number of approvals for antibody drug conjugates globally is anticipated to generate additional opportunities for contract manufacturing firms specializing in this sector, thereby driving growth and innovation within the Global Antibody Drug Conjugates Contract Manufacturing market. The overall landscape remains dynamic, reflecting the increasing importance of these advanced therapeutics.

Restraints in the Global Antibody Drug Conjugates Contract Manufacturing Market

The global market for antibody drug conjugates contract manufacturing faces several challenges that could impede its growth. The complexity of the design, development, and production processes necessitates specialized facilities capable of handling antibodies, cytotoxic drugs, and conjugation, leading to substantial capital investments. Additionally, the high costs associated with research and development, stemming from the rigorous preclinical and clinical testing required to demonstrate safety and efficacy, may act as a barrier to demand. Such financial strains could hinder the viability and expansion of the contract manufacturing sector within this niche pharmaceutical market.

Market Trends of the Global Antibody Drug Conjugates Contract Manufacturing Market

The Global Antibody Drug Conjugates Contract Manufacturing market is witnessing a robust trend towards strategic collaborations and capacity expansions among contract manufacturing organizations (CMOs). Companies in this sector are prioritizing the establishment of partnerships with pharmaceutical innovators to create secure supply chains and ensure dedicated manufacturing slots, thereby mitigating potential bottlenecks. Additionally, the ongoing demand for scalable and flexible manufacturing solutions is driving CMOs to enhance their operational capabilities. This focus on maximizing business scope and flexibility is expected to solidify the role of antibody drug conjugates in innovative therapeutics, shaping a dynamic landscape in the contract manufacturing market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Raw Material Analysis

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Stage of Development & CAGR (2025-2032)

• Market Overview
• Phase I
• Phase II
• Phase III

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Process Component & CAGR (2025-2032)

• Market Overview
• Antibody
• HPAPI / Cytotoxic Payload
• Conjugation / Linker
• Fill / Finish

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Target Indication & CAGR (2025-2032)

• Market Overview
• Solid Tumors
• Hematological Tumors
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Generation & CAGR (2025-2032)

• Market Overview
• Second Generation
• Third Generation
• Fourth Generation
• Next Generation

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Origin & CAGR (2025-2032)

• Market Overview
• Humanized
• Chimeric
• Murine
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Type of Linker & CAGR (2025-2032)

• Market Overview
• Maleimide
• SMCC
• Tetrapeptide-based linker
• Valine-citrulline
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies - 30%
• Academic & Research Institutes
• Others

Global Antibody Drug Conjugates Contract Manufacturing Market Size & CAGR (2025-2032)

• North America (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • US
  • Canada
• Europe (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi XDC (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Pharma Solutions (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MilliporeSigma (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sterling Pharma Solutions (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cerbios-Pharma SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CARBOGEN AMCIS (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abzena PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (Cayman Islands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ajinomoto Bio-Pharma Services (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axplora (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Contract Manufacturing (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Formosa Laboratories (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veranova (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations